Samuel J Reich insider trades
Open-market stock purchases and sales by Samuel J Reich, CEO at SAB Biotherapeutics, Inc, from SEC Form 4 filings since Jan 14, 2021.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +240%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Feb 3, 2026 | SABS SAB Biotherapeutics, Inc | Bought (not open market) | — |